Home    Contact Us    Send to Colleague    Search 

   T H A N K   Y O U      F O R   Y O U R   I N T E R E S T


28 Jan 2020
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space.  US rights only. Asset has significant intellectual property rights.  This p... View Release

You information has been sent.

Thank you for you interest in Commercial Healthcare Partners.  Someone will contact you shortly.

The CHP Team


Dec 19 2020
Marketed products in the GI space

Marketed product in the GI space (idiopathic bowel syndrome, diarrhea, opioid induced constipation) available for acquisition.  Client will also consider a distribution partnership. 

Add to Outlook Calendar

Dec 4 2020
Manufacturing facilities needed

Buy side client seeks to acquire manufacturing facilities in the US.  Sterile manufacturing capabilities highly desired. 

Will consider non-sterile facility with excess capacity. 

Add to Outlook Calendar

Nov 6 2020
Company with sleep apnea asset seeks development partner

First sleep apnea oral therapy available for co-development.  Phase II study completed with positive results.  Company has completed first round of financing raising $40 million.  Market is highly unsatisfied. Strong IP protection through 2039.  Company seeks $120 million to complete Phase III clinical trials.

Add to Outlook Calendar

Oct 10 2020
Chemotherapy induced nausea and vomiting product available for in-licensing

Polysorbate free 505(b)(2) product available for in-licensing in the US market.  Advantages over other comparable products include favorable side effect profile and ready to use solution.  Market research conducted with hospital pharmacists and chemotherapy clinics indicate that the product will be accepted in the marketplace upon approval.

Add to Outlook Calendar

Sep 20 2020
Schizophrenia asset available for in-licensing

505(b)(2) product for the treatment of schizophrenia available for in-licensing.  Multiple markets available including the US.  NDA filed in the US in 2019. Approval expected in 2021.  Oral dissolving film makes this product beneficial for patients who resist swallowing.  All studies have been completed and a complete response letter issued by the FDA.  Manufactured in FDA approved facility.

Add to Outlook Calendar

© 2021 by Commercial Healthcare Partners. Website Design & Development by Birchwood Group   Commercial Healthcare Partners    Jim Usry